Feedback PLC Team

The Feedback team brings together a wealth of knowledge and expertise from medical and specialist IT healthcare backgrounds.

We have professional experience from real-life medical and scientific research environments. Having previously worked in close cooperation with researchers, radiologists and IT specialists, we believe our unique skills ensure confidence in our imaging technologies and provide relevance in today’s medical world. Key personnel of the Feedback team include Dr Alastair Riddell, Feedback plc’s Chairman, Professor Rory Shaw, our Medical Director, Dr Balaji Ganeshan, one of the founders of TexRAD, Mike Hayball and Dr Stephen Brown, the creators of Cadran.

Feedback Team

Feedback PLC Board of Directors

Dr Tom Oakley

Dr Tom Oakley

Chief Executive Officer

View Bio +

Dr Tom Oakley

Chief Executive Officer

Dr Tom Oakley joins Feedback plc as Chief Executive Officer. Dr Oakley is a qualified radiologist with significant clinical and academic experience, he also holds a successful track record of entrepreneurial activity. This includes serving as Director of NHS services at Synergix Health, where he led the launch of telemedicine services to 40,000 patients. In 2016, he founded Innovation Doctor Ltd, aimed at exploring the digital healthcare space and supporting digital start-ups and SMEs. As Medical Director of 3D LifePrints, a medical 3D printing company, he has helped expand their services into 20 NHS trusts.

Dr Alastair Riddell

Dr Alastair Riddell

Non-Executive Chairman

View Bio +

Dr Alastair Riddell

Non-Executive Chairman

Dr Riddell has over 30 years experience in healthcare, with 18 years as a main board director. After 10 years directing phases 1-4 clinical trials for companies including Lederle (now Pfizer) and Centocor (now J&J), he spent five years managing sales and marketing for oncology and imaging products for Amersham International (now GE Healthcare). This led to 12 years as CEO for three UK biotech companies, Pharmagene, Paradigm Therapeutics and Stem Cell Sciences. In these roles he completed a successful IPO on the LSE’s main market and two trade sales.

Lindsay Melvin

Lindsay Melvin

Chief Financial Officer

View Bio +

Lindsay Melvin

Chief Financial Officer

Lindsay is a chartered accountant and brings 30 years of financial and business experience. Most recently he was Chief Executive Officer of the Chartered Institute of Payroll Professionals (CIPP) for eight years until July 2016. CIPP was voted the UK’s best association in the 2016 Associations Excellence Awards and was also voted as one of the Sunday Times ‘Best 100 Not for Profit Organisations’ in 2016. Lindsay was Finance Director for Arthur Shaw & Co plc for six years. Lindsay started his career at Grant Thornton where he spent 11 years.

Professor Tim Irish

Professor Tim Irish

Non-Executive Director

View Bio +

Professor Tim Irish

Non-Executive Director

Tim has worked in the life sciences industry for 30 years. His career has spanned global health technology companies across Europe and North America, including GSK, GE and Philips - the latter two in senior positions responsible for medical imaging. Tim is a Professor of Practice at Kings College London and a board member of Bournemouth University. Tim joined the board of the National Institute for Health and Care Excellence (NICE) in April 2015 and became the Senior Independent Director in May 2017. Tim currently holds a number of non-executive positions in health and technology related entities.

Simon Sturge

Simon Sturge

Non-Executive Director

View Bio +

Simon Sturge

Non-Executive Director

Simon is an experienced healthcare executive in the UK and has built a very strong reputation, not only in the biotechnology industry but also in the investment community. He joined Merck Healthcare in 2014 and is currently Chief Operating Officer and member of their Healthcare Executive Committee. His experience includes eight years at Celltech, and he was the founder and CEO of RiboTargets (which later reversed into Vernalis Plc). After serving as CEO of OctoPlus N.V. for two years, he became Senior Vice President of Boehringer Ingelheim's Biopharmaceutical Business.